Document is current
Any future updates will be listed below
-
Authors
Bergwik, Jesper
Liu, Jielu
Padra, Médea
Bhongir, Ravi K. V.
Tanner, Lloyd
Xiang, Yujiao
Lundblad, Mia
Egesten, Arne
Adner, Mikael
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2020-011166, 2019-01630)
The Swedish Government Funds for Clinical Research The Swedish Government Funds for Clinical Research (46402)
VINNOVA
Hjärt-Lungfonden (20190160, 20210297)
Alfred Österlunds Stiftelse
Karolinska Institute
- License Information
-
More Information
Article History
Received: 23 October 2023
Accepted: 17 March 2024
First Online: 30 March 2024
Declarations
:
: All procedures involving human tissue were in accordance with the ethical standards of the relevant institution and/or national research committee of each collection site, REPROCELL’s ethical approval for use of human tissue (West of Scotland Research Ethics Service 17/WS/0049), and the amended Helsinki Declaration. Informed written consent was obtained from all individual participants or their nominated persons. Procedures involving rat and dog tissues were performed in accordance with the UK Animal Welfare Act 2006. Murine experiments were approved by the Malmö-Lund Animal Care Ethics Committee (ethical permit no. 3802-19) and the Stockholm Animal Care Ethics Committee (ethical permit no. 3649-2019).
: Not applicable.
: A joint grant from VINNOVA was provided to Arcede Pharma AB and AE as mentioned above. AE has received a honorar as an advisor from Arcede Pharma AB that holds a patent for RCD405. MA has received funding from Arcede Pharma AB to conduct experiments for the study. ML is employed by Arcede Pharma AB.
